Bruker
BRKR
$59.74
-1.14%
Bruker Corporation manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. As a leader in advanced analytical and diagnostic solutions, Bruker distinguishes itself through its broad portfolio spanning mass spectrometry, microscopy, and superconductor technologies. The current investor narrative centers on the company's growth trajectory, driven by its BSI CALID segment and recent product innovations, while debates focus on margin expansion and the impact of currency fluctuations on revenue.…
BRKR
Bruker
$59.74
Investment Opinion: Should I buy BRKR Today?
Rating: Hold. Bruker is a speculative turnaround story with improving margins but still-weak profitability. The consensus analyst rating is Buy with an average target of $59.75, implying modest 2.6% upside. However, the risk/reward is balanced given the low net margin and decelerating revenue growth.
Supporting Evidence: The trailing P/S of 2.08x is a 41% discount to the industry average of 3.5x, suggesting value. Revenue grew 2.75% YoY in Q1 2026, but this is below the industry norm. Gross margin improved to 47.3% from 45.9% in Q4 2025, a positive sign. Free cash flow turned positive at $47 million in Q1 2026. However, the forward P/E of 23.97x is in line with the sector, implying the market already expects a recovery. The stock's 38% 1-year gain already reflects optimism.
Risks & Conditions: The biggest risks are failure to sustain margin improvement and revenue deceleration below 2%. This Hold would upgrade to Buy if the forward P/E compresses below 20x or if revenue growth accelerates above 5%. It would downgrade to Sell if net margins remain below 2% for two consecutive quarters. Valuation verdict: The stock appears fairly valued relative to forward earnings but undervalued on P/S, reflecting the market's skepticism about near-term profitability.
Sign up to view all
BRKR 12-Month Price Forecast
Bruker is a neutral outlook given the balanced risk/reward. The stock has strong momentum and a low P/S ratio, but profitability is thin and revenue growth is slow. The base case of modest improvement to the analyst average target seems most likely. An upgrade to bullish would require clear evidence of margin expansion and revenue acceleration, while a downgrade to bearish would follow a deterioration in fundamentals. The key factor to watch is whether net margins can sustainably exceed 3%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Bruker's 12-month outlook, with a consensus price target around $59.75 and implied upside of +0.0% versus the current price.
Average Target
$59.75
0 analysts
Implied Upside
+0.0%
vs. current price
Analyst Count
—
covering this stock
Price Range
$40 - $70
Analyst target range
Bruker is covered by 12 analysts, with a consensus recommendation of 'Buy' (mean score 2.08 on a 1-5 scale, where 1 is Strong Buy). The average target price is $59.75, implying a modest 2.6% upside from the current price of $58.23. The distribution shows 6 Buy/Overweight ratings, 4 Hold/Neutral, and 2 Sell/Underweight, indicating a generally bullish but cautious sentiment. Recent ratings from Citigroup (Neutral), Leerink (Outperform), Guggenheim (Buy), Barclays (Overweight), and JP Morgan (Overweight) suggest institutional confidence, though no recent upgrades or downgrades have occurred. The target price range spans from $40.00 (low) to $70.00 (high), representing a wide spread of $30.00, which signals high uncertainty. The low target of $40 implies a 31% downside, potentially pricing in margin compression or competitive losses, while the high target of $70 suggests 20% upside, assuming accelerating growth and multiple expansion. The wide range reflects divergent views on the company's ability to sustain its recent recovery and achieve profitability targets.
Bulls vs Bears: BRKR Investment Factors
Bruker presents a mixed picture: strong price momentum and a discounted P/S ratio suggest value, but razor-thin profitability and decelerating revenue growth raise concerns. The bull case hinges on margin expansion and a return to profitability, which analysts expect (forward P/E 23.97x). The bear case warns that the current valuation already prices in that recovery, leaving little room for error. The single most important tension is whether Bruker can translate its gross margin improvement into sustainable net income growth. Currently, the evidence slightly favors the bulls given the strong technical trend and low P/S, but the margin for error is slim.
Bullish
- Strong price momentum and relative strength: BRKR has gained 38% over the past year and 43% over the past 3 months, significantly outperforming the S&P 500's 18% and 4.7% gains, respectively. The stock's relative strength of +19.7% over 1 year confirms sustained outperformance.
- Undervalued on P/S vs industry and history: The trailing P/S ratio of 2.08x is 41% below the industry average of 3.5x and near the low end of its historical range (6.7x-20.1x). This suggests the market is pricing in the recent earnings weakness, offering a potential value entry if profitability recovers.
- Analyst consensus Buy with upside potential: 12 analysts rate BRKR a Buy (mean 2.08 on 1-5 scale), with an average target of $59.75 implying 2.6% upside. The high target of $70 suggests 20% upside, reflecting optimism about margin recovery and growth.
- Improving gross margin and free cash flow: Gross margin improved to 47.3% in Q1 2026 from 45.9% in Q4 2025, and free cash flow turned positive at $47 million in Q1 2026 versus negative in prior quarters. This indicates operational efficiency gains and better cash generation.
Bearish
- Very low profitability and negative ROE: Net margin is only 1.75% in Q1 2026, and trailing EPS is -$0.0012, resulting in a negative ROE of -0.35%. The company is barely profitable, making it vulnerable to any revenue shortfall.
- Revenue growth decelerating to 2.75% YoY: Q1 2026 revenue grew only 2.75% YoY to $823.4 million, down from 4.5% growth in Q1 2025. This is below the medical devices industry average, suggesting a mature or challenged top-line trajectory.
- High valuation on forward earnings: The forward P/E of 23.97x is in line with the sector median of ~25x, but this assumes a significant earnings recovery. If profitability disappoints, the stock could de-rate, especially given the negative trailing P/E.
- Wide analyst target range signals uncertainty: Analyst targets range from $40 (31% downside) to $70 (20% upside), a $30 spread. This high dispersion reflects deep disagreement about the company's ability to sustain its recovery and achieve profitability targets.
BRKR Technical Analysis
Bruker's stock is in a strong uptrend, with a 1-year price change of +38.0% and currently trading at $58.23, which is 90.2% of its 52-week range ($28.53-$64.54). This positioning near the high end of the range suggests bullish momentum, though it also indicates the stock may be approaching overbought territory. The 1-year relative strength versus SPY is +19.7%, confirming outperformance. Short-term momentum is accelerating, with 1-month and 3-month price changes of +6.4% and +43.1%, respectively, both outpacing the S&P 500's gains of 0.3% and 4.7%. The 3-month surge is particularly notable, indicating a sharp recovery from the March lows near $32.76. However, the 1-month change of +6.4% is a deceleration from the 3-month pace, suggesting a potential consolidation phase. The stock's beta of 1.293 implies 29% higher volatility than the market, which aligns with the recent sharp moves. Key support lies at the 52-week low of $28.53, while resistance is at the 52-week high of $64.54. A breakout above $64.54 would signal a continuation of the uptrend, while a breakdown below $58.23 (recent close) could test the $54 area. The 52-week range width of $36.01 indicates significant volatility, and the beta of 1.293 confirms above-market risk.
Beta
1.29
1.29x market volatility
Max Drawdown
-39.9%
Largest decline past year
52-Week Range
$29-$65
Price range past year
Annual Return
+54.0%
Cumulative gain past year
| Period | BRKR Return | S&P 500 |
|---|---|---|
| 1m | +5.7% | +0.4% |
| 3m | +64.9% | +5.5% |
| 6m | +18.7% | +8.4% |
| 1y | +54.0% | +18.9% |
| ytd | +24.2% | +9.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
BRKR Fundamental Analysis
Bruker's revenue trajectory shows modest growth, with Q1 2026 revenue of $823.4 million, up 2.75% year-over-year from $801.4 million in Q1 2025. However, the multi-quarter trend reveals deceleration: Q4 2025 revenue was $977.2 million, and Q3 2025 was $860.5 million, indicating seasonal fluctuations but a generally flat-to-slightly-growing top line. The BSI CALID segment is the primary revenue driver, though segment-specific data is limited. The 2.75% YoY growth is below the industry average for medical devices, suggesting a mature growth phase. Profitability is weak, with net income of $14.4 million in Q1 2026, resulting in a net margin of 1.75%. Gross margin improved to 47.3% in Q1 2026 from 45.9% in Q4 2025, but operating margin remains low at 5.5%. The company has been barely profitable over the trailing twelve months, with EPS of -$0.0012, indicating that profitability is fragile. The balance sheet shows a debt-to-equity ratio of 0.83, which is moderate, and a current ratio of 1.73, indicating adequate liquidity. Free cash flow was $47 million in Q1 2026, improving from negative free cash flow in prior quarters, but the TTM free cash flow of $51.3 million is low relative to the market cap. ROE is negative at -0.35%, reflecting the thin profitability. The company generates enough cash to cover capex but relies on debt financing for growth, as seen in the $181.3 million debt repayment in Q1 2026.
Quarterly Revenue
$823400000.0B
2026-03
Revenue YoY Growth
+2.8%
YoY Comparison
Gross Margin
47.3%
Latest Quarter
Free Cash Flow
$51300000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is BRKR Overvalued?
Since net income is negative on a trailing basis (EPS -$0.0012), the trailing P/E is not meaningful, so we use the P/S ratio. The trailing P/S is 2.08x, while the forward P/E is 23.97x, implying that analysts expect a return to profitability. The gap between the negative trailing P/E and positive forward P/E suggests the market anticipates a significant earnings recovery. Compared to the industry average P/S of 3.5x (estimated), Bruker's 2.08x represents a 41% discount, which may reflect its low profitability and growth concerns. However, the forward P/E of 23.97x is in line with the sector median of ~25x, indicating that the market is pricing in normalized earnings. Historically, Bruker's P/S ratio has ranged from 6.7x (Q1 2026) to 20.1x (Q2 2021), with the current 2.08x near the low end of its historical band. This suggests the stock is undervalued relative to its own history, but the low multiple is justified by the recent earnings weakness. The P/B ratio of 2.91x is also below the historical average of ~8x, further indicating a potential value opportunity if profitability improves.
PE
-314.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 13x~206x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
29.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Bruker's primary financial risk is its fragile profitability. With a net margin of just 1.75% in Q1 2026 and negative trailing EPS (-$0.0012), the company has little buffer against revenue declines. The debt-to-equity ratio of 0.83 is moderate, but interest expense of $12.2 million in Q1 2026 consumes a significant portion of operating income ($45 million). Free cash flow improved to $47 million in Q1 2026, but the TTM free cash flow of $51.3 million is low relative to the $7.15 billion market cap, implying a high price-to-cash-flow ratio of 53.3x. Revenue concentration in the BSI CALID segment adds risk if that segment faces headwinds.
Market & Competitive Risks: The stock's beta of 1.293 indicates 29% higher volatility than the market, making it sensitive to macro shocks. The forward P/E of 23.97x is in line with the sector, but if the expected earnings recovery fails to materialize, the multiple could contract sharply. The wide analyst target range ($40-$70) highlights high uncertainty. Competitive risks include pricing pressure in scientific instruments and potential disruption from new technologies. No recent news is available, but the lack of catalysts could lead to stagnation.
Worst-Case Scenario: If revenue growth stalls below 2% and margins fail to expand, the stock could fall to the analyst low target of $40, representing a 31% decline from the current $58.23. This would also approach the 52-week low of $28.53, implying a potential 51% loss. The worst-case scenario could be triggered by a macroeconomic downturn that delays capital spending by Bruker's customers, combined with a failure to achieve cost savings. In such a scenario, the stock could test the $40 level, a 31% downside.
FAQ
The primary risk is financial: net margin of 1.75% leaves no room for error—any revenue shortfall could lead to losses. Second, revenue growth is decelerating (2.75% YoY), below industry averages, indicating potential market share loss or mature end markets. Third, the stock's beta of 1.293 makes it vulnerable to macro downturns. Fourth, the wide analyst target range ($40-$70) signals high uncertainty about the company's trajectory. The most severe risk is a failure to achieve the expected earnings recovery, which could trigger a 31% decline to $40.
The 12-month forecast is balanced. The base case (50% probability) sees the stock trading around the analyst average target of $59.75, with modest revenue growth of 2-4% and stable margins. The bull case (25% probability) targets $65-$70, driven by margin expansion and revenue acceleration above 5%. The bear case (25% probability) sees the stock falling to $40-$48 if margins deteriorate or growth stalls. The most likely scenario is the base case, assuming gradual improvement in profitability.
BRKR appears undervalued on a trailing P/S basis (2.08x vs industry 3.5x) and relative to its own history (P/S historically 6.7x-20.1x). However, the forward P/E of 23.97x is in line with the sector median of ~25x, suggesting the market is pricing in a return to profitability. The low P/S reflects the market's skepticism about near-term earnings. Overall, the stock is fairly valued on forward earnings but undervalued on sales, implying that if profitability improves, the stock could re-rate higher.
BRKR offers a compelling risk/reward for investors willing to bet on a turnaround. The stock trades at a 41% discount to its industry on a P/S basis (2.08x vs 3.5x), and analysts see 2.6% upside to the average target of $59.75. However, the company is barely profitable with a net margin of 1.75% and negative trailing EPS. The biggest downside risk is a failure to improve margins, which could send the stock to $40 (31% downside). For aggressive investors with a 12-month horizon, it could be a good buy if they believe margins will expand. Conservative investors should wait for clearer evidence of sustainable profitability.
BRKR is better suited for a medium-term investment of 12-24 months, given its turnaround nature and high volatility (beta 1.293). Short-term traders may benefit from momentum (38% 1-year gain), but the stock is near the top of its 52-week range, limiting upside. Long-term investors should wait for more consistent profitability before committing. The stock pays a negligible dividend (0.32% yield), so it offers no income. A minimum holding period of 12 months is recommended to allow the turnaround thesis to play out.